guest ::
| Home > Publications database > Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. > print |
| Home > Publications database > Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. > print |
| 001 | 125893 | ||
| 005 | 20240228143339.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-016-3346-0 |2 doi |
| 024 | 7 | _ | |a pmid:26971788 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC4906063 |2 pmc |
| 024 | 7 | _ | |a 0340-6997 |2 ISSN |
| 024 | 7 | _ | |a 1432-105X |2 ISSN |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 024 | 7 | _ | |a altmetric:6192788 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-02017 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Giesel, Frederik |0 P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2016 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1524733326_26429 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Multi-parametric magnetic resonance imaging (MP-MRI) is currently the most comprehensive work up for non-invasive primary tumor staging of prostate cancer (PCa). Prostate-specific membrane antigen (PSMA)-Positron emission tomography-computed tomography (PET/CT) is presented to be a highly promising new technique for N- and M-staging in recurrent PCa-patients. The actual investigation analyses the potential of (68)Ga-PSMA11-PET/CT to assess the extent of primary prostate cancer by intra-individual comparison to MP-MRI.In a retrospective study, ten patients with primary PCa underwent MP-MRI and PSMA-PET/CT for initial staging. All tumors were proven histopathological by biopsy. Image analysis was done in a quantitative (SUVmax) and qualitative (blinded read) fashion based on PI-RADS. The PI-RADS schema was then translated into a 3D-matrix and the euclidian distance of this coordinate system was used to quantify the extend of agreement.Both MP-MRI and PSMA-PET/CT presented a good allocation of the PCa, which was also in concordance to the tumor location validated in eight-segment resolution by biopsy. An Isocontour of 50 % SUVmax in PSMA-PET resulted in visually concordant tumor extension in comparison to MP-MRI (T2w and DWI). For 89.4 % of sections containing a tumor according to MP-MRI, the tumor was also identified in total or near-total agreement (euclidian distance ≤1) by PSMA-PET. Vice versa for 96.8 % of the sections identified as tumor bearing by PSMA-PET the tumor was also found in total or near-total agreement by MP-MRI.PSMA-PET/CT and MP-MRI correlated well with regard to tumor allocation in patients with a high pre-test probability for large tumors. Further research will be needed to evaluate its value in challenging situation such as prostatitis or after repeated negative biopsies. |
| 536 | _ | _ | |a 315 - Imaging and radiooncology (POF3-315) |0 G:(DE-HGF)POF3-315 |c POF3-315 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)) |2 NLM Chemicals |
| 650 | _ | 7 | |a Oligopeptides |2 NLM Chemicals |
| 650 | _ | 7 | |a Edetic Acid |0 9G34HU7RV0 |2 NLM Chemicals |
| 700 | 1 | _ | |a Sterzing, F. |b 1 |
| 700 | 1 | _ | |a Schlemmer, H. P. |0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |b 2 |u dkfz |
| 700 | 1 | _ | |a Holland-Letz, T. |0 P:(DE-He78)457c042884c901eb0a02c18bb1d30103 |b 3 |u dkfz |
| 700 | 1 | _ | |a Mier, W. |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Rius, M. |b 5 |
| 700 | 1 | _ | |a Afshar-Oromieh, A. |0 P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c |b 6 |u dkfz |
| 700 | 1 | _ | |a Kopka, K. |0 P:(DE-He78)9793347ba83f527b81a22ab75af9378a |b 7 |u dkfz |
| 700 | 1 | _ | |a Debus, J. |0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |b 8 |u dkfz |
| 700 | 1 | _ | |a Haberkorn, U. |0 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558 |b 9 |u dkfz |
| 700 | 1 | _ | |a Kratochwil, C. |b 10 |
| 773 | _ | _ | |a 10.1007/s00259-016-3346-0 |g Vol. 43, no. 8, p. 1400 - 1406 |0 PERI:(DE-600)2098375-X |n 8 |p 1400 - 1406 |t European journal of nuclear medicine and molecular imaging |v 43 |y 2016 |x 1619-7089 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:125893 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)457c042884c901eb0a02c18bb1d30103 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)9793347ba83f527b81a22ab75af9378a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-315 |2 G:(DE-HGF)POF3-300 |v Imaging and radiooncology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E060-20160331 |k E060 |l KKE Nuklearmedizin |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l Radiologie |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l KKE Strahlentherapie |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)E030-20160331 |k E030 |l Radiopharmazeutische Chemie |x 4 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E010-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E050-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E030-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|